Home > Healthcare > Medical Devices > Therapeutic Devices > Hemodialysis Equipment Market

Hemodialysis Equipment Market Trends

Report ID: GMI8038
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Hemodialysis Equipment Market Trends

Technological integration for home hemodialysis is reshaping the landscape of renal care for providing patients with enhanced convenience and autonomy, subsequently adding to the industry growth. As technology continues to advance, home hemodialysis equipment is becoming increasingly sophisticated for allowing seamless integration into everyday life. This advancement is empowering patients to manage their treatment independently, leading to better outcomes and higher quality of life for individuals to cater to their health needs.

For instance, in August 2023, Fresenius received FDA approval for its dialysis software, GuideMe. This software is accessible to U.S. users of Fresenius' VersiHD dialysis machines, which is cleared for solo and overnight use. The software simplifies the setup and enhances mobility for facilitating at-home dialysis sessions, marking a significant advancement in patient care.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global hemodialysis equipment industry was valued at around USD 14 billion in 2023 and is estimated to reach over USD 24.4 billion by 2032, driven by the increasing prevalence of kidney diseases.

The hospitals segment accounted for around USD 5.9 billion in 2023, attributed to the capacity of these healthcare settings to effectively care for high-acuity patients, including those facing conditions such as kidney failure, sepsis, and shock.

North America hemodialysis equipment market accounted for USD 5.7 billion in 2023 and will continue to grow through 2032, owing to a heightened prevalence of chronic diseases.

Asahi Kasei Corporation., Toray Industries, Inc., Baxter International Inc., Rockwell Medical Technologies Inc., B. Braun Melsungen AG, Nikkiso Co., Ltd, Diaverum Holding AB, Nipro Corporation, DaVita Inc. and Fresenius Medical Care AG & Co. KGaA